—
C+
C+ The full Closelook — membership. Open the C+ overview

Charles River Laboratories (CRL) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Charles River Laboratories

CRL in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotech developers worldwide. It breeds and sells research rodents, runs in vitro and in vivo testing for new drug candidates, and offers manufacturing and quality-control testing for biologics. Its clients range from early discovery labs to companies preparing therapies for regulatory review. It is headquartered in Wilmington, United States, and trades on a US exchange.
Where it sits in the stack
Charles River sits outside Rubin, our AI build-out index; it belongs instead to the diary's healthcare and life-sciences universe, where it acts as a testing and research-services provider that drug developers rely on to move compounds through non-clinical stages before trials begin.
Who it is priced against
Closelook's peer group has not been set for this name; the company most often named alongside it is IQVIA, another contract research organisation serving drug developers through the clinical pipeline.
Why Closelook tracks it
It sits in the S&P 500; Closelook has not yet built a score for it, so its module read is still being assembled as coverage widens.
What the diary watches
Whether biotech funding cycles lift or slow demand for outsourced testing and research-model work, since that flow feeds directly into the segments Charles River reports.

Charles River Laboratories (CRL) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for CRL, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by Argus, 2026-09-17

The Street on this name

Analyst actions and the latest print for CRL from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Argus — target 330 from 250 Target raised to $330 from $250 (+18.1% to spot) 2026-09-17
  • Price target Evercore ISI — target 320 from 300 Target raised to $320 from $300 (+15.4% to spot) 2026-09-11

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Charles River Laboratories (CRL)?

Charles River Laboratories trades as CRL on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is CRL in a Closelook index?

Not currently — Charles River Laboratories is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does CRL trade against its moving averages?

Uptrend stack intact: Trades +7.3% vs the 50-day and +37.8% vs the 200-day average, 7.1% below the 52-week high and +95.3% off the 52-week low; a golden cross printed 53 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Charles River Laboratories do?

Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotech developers worldwide. It breeds and sells research rodents, runs in vitro and in vivo testing for new drug candidates, and offers manufacturing and quality-control testing for biologics. Its clients range from early discovery labs to companies preparing therapies for regulatory review. Closelook's peer group has not been set for this name; the company most often named alongside it is IQVIA, another contract research organisation serving drug developers through the clinical pipeline.

Where does Charles River Laboratories sit in the AI build-out?

Charles River sits outside Rubin, our AI build-out index; it belongs instead to the diary's healthcare and life-sciences universe, where it acts as a testing and research-services provider that drug developers rely on to move compounds through non-clinical stages before trials begin. It sits in the S&P 500; Closelook has not yet built a score for it, so its module read is still being assembled as coverage widens.

What has Wall Street done on Charles River Laboratories recently?

The most recent analyst action on Charles River Laboratories on the Closelook wire is a price target by Argus on 2026-09-17 (target 330 from 250). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for CRL, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe